[The pharmacodynamics of the new anti-arrhythmia preparation bonnecor based on the data from an acute drug test].
The pharmacodynamics of the new antiarrhythmic agent bonnecor was studied in 33 patients with coronary heart diseases and ventricular arrhythmias in the acute drug test. The parenteral formulation of the drug (0.04-0.8 mg/kg) and its tablets were given to 23 and 27 patients, respectively. Bonnecor was found to be effective in suppressing ventricular premature contractions. Its intravenous and oral efficacy is 65 and 70%), respectively. During intravenous injection, the drug showed its antiarrhythmic effect on an average of 14 minutes later, lasting about 68 minutes. During oral administration, the action of the drug started 0.5 hour later and lasted 7.2 hours. Adverse reactions were rare. An echocardiographic study revealed its negative inotropic effect which is likely to be insignificant since there was no development or increase of heart failure in any of the examinees (including 8 patients with signs of Stage I-IIA circulatory insufficiency).